Neurocrine Biosciences Inc

Slēgts

SektorsVeselības aprūpe

174.15 4.15

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

171

Max

174.2

Galvenie mērījumi

By Trading Economics

Ienākumi

44M

198M

Pārdošana

9M

815M

P/E

Sektora vidējais

25.926

56.269

EPS

1.94

Peļņas marža

24.297

Darbinieki

2,000

EBITDA

19M

254M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+10.91% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 29. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.5B

17B

Iepriekšējā atvēršanas cena

170

Iepriekšējā slēgšanas cena

174.15

Ziņu noskaņojums

By Acuity

13%

87%

9 / 342 Rangs Healthcare

Neurocrine Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. jūl. 23:41 UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026. g. 2. jūl. 23:32 UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

2026. g. 2. jūl. 23:31 UTC

News
Social Media
ETF Constituents
Correlated Moves

The Nasdaq 100 Index is higher in after-market hours, buoyed by U.S. jobless data and positive contributions from Microsoft, Meta, and Texas Instruments.

2026. g. 2. jūl. 23:26 UTC

News

O'Reilly Automotive's $10 billion bid for Genuine Parts' division coincides with a decline in shares during after-market trading. Genuine Parts' shares rose significantly.

2026. g. 2. jūl. 23:26 UTC

News

Qualcomm shares are higher in after-market hours despite Elon Musk's denial of a partnership with SpaceX and removal from Russell indexes.

2026. g. 2. jūl. 23:16 UTC

Correlated Moves
News
Macro News
ETF Constituents

Vanguard Information Technology ETF gains after-hours, supported by positive contributions from Microsoft and Texas Instruments, following favorable U.S. jobless data.

2026. g. 2. jūl. 23:16 UTC

News

Microchip Technology Inc shares are higher in after-market trading, despite concerns over AI-driven chip demand and a recent pullback in the Philadelphia Semiconductor Index.

2026. g. 2. jūl. 23:12 UTC

News

Applied Materials shares advanced in after-hours trading, buoyed by positive equity market sentiment and gains in European indices like the DAX.

2026. g. 2. jūl. 23:11 UTC

News
Macro Event
Correlated Moves

The USD/CZK exchange rate is lower today, reflecting recent U.S. labor market data and broader market sentiment influencing currency movements.

2026. g. 2. jūl. 23:11 UTC

Macro Event
News

The USD/PLN exchange rate is lower today, reflecting a decline since Wednesday's close amid mixed U.S. labor market data and unusual volatility.

2026. g. 2. jūl. 23:11 UTC

News
Social Media
Correlated Moves

The EUR/HKD exchange rate is rising, supported by U.S. Dollar weakness after disappointing nonfarm payroll data and positive GBP/USD movements.

2026. g. 2. jūl. 23:11 UTC

News
Macro Event

The U.S. Dollar weakened against the Danish Krone following disappointing June nonfarm payroll data, which showed only 57,000 jobs added.

2026. g. 2. jūl. 23:11 UTC

News
Social Media
Correlated Moves

Weakness in the U.S. Dollar, following disappointing payroll data, supports gains in GBP/HKD during Thursday's session. The asset is higher since Wednesday's close.

2026. g. 2. jūl. 23:11 UTC

News
Macro Event
Correlated Moves

The USD/NOK exchange rate is lower, influenced by weaker U.S. job growth and correlated declines in USD/CAD. Volatility remains notable during Thursday's session.

2026. g. 2. jūl. 23:11 UTC

Correlated Moves
News

Bitcoin remains higher despite SBI Crypto's cessation of mining operations. Earlier in the session, it pulled back from a peak amid significant volatility.

2026. g. 2. jūl. 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

2026. g. 2. jūl. 23:06 UTC

Correlated Moves
News

Gold trades slightly higher in after-market hours, supported by a modest rise in silver and tempered rate hike expectations following a weaker jobs report.

2026. g. 2. jūl. 23:01 UTC

Macro Event
News

The USD/ZAR exchange rate is lower today, impacted by weaker U.S. Non-Farm Payrolls data revealing only 57,000 jobs added in June.

2026. g. 2. jūl. 22:51 UTC

Macro Event
News

The Nikkei 225 Index declined in after-market hours, pressured by a sell-off in semiconductor shares and strengthened yen amid government intervention expectations.

2026. g. 2. jūl. 20:13 UTC

ETF Constituents
News

Vanguard Large-Cap ETF declines after market close, influenced by broader market conditions and weaker U.S. jobs data. Holdings like Google and Johnson & Johnson also posted losses.

2026. g. 2. jūl. 20:13 UTC

News
Correlated Moves

The Japanese yen strengthened to a two-week high against the U.S. dollar amid global uncertainties, while Invesco Currencyshares Japanese Yen Trust is trading roughly flat after hours.

2026. g. 2. jūl. 20:07 UTC

Correlated Moves
News
Macro Event

The USD/HUF exchange rate is declining amid disappointing US job growth and a weaker US Dollar Index, with notable intraday volatility.

2026. g. 2. jūl. 20:06 UTC

News

Liberty Global shares are higher as Liberty Latin America is added to several Russell Growth indices, potentially boosting visibility to passive funds and investors.

2026. g. 2. jūl. 20:06 UTC

Correlated Moves
News
Macro Event

The USD/SGD exchange rate is lower today, reflecting pressure from weaker U.S. job growth data and a declining U.S. Dollar Index.

2026. g. 2. jūl. 20:06 UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026. g. 2. jūl. 20:06 UTC

News
Correlated Moves

Gold prices rise amid weaker U.S. jobs data, which reported only 57,000 new jobs. Easing oil prices and rising silver also support gold's appeal.

2026. g. 2. jūl. 20:06 UTC

News
Correlated Moves

Gold prices are higher today, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026. g. 2. jūl. 20:06 UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026. g. 2. jūl. 20:05 UTC

Correlated Moves
Social Media
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is underperforming, reflecting a decline in the Communications sector. The fund remains roughly flat since Wednesday's close.

2026. g. 2. jūl. 20:05 UTC

News
Social Media

Tesla Inc's stock is declining amid profit-taking despite strong delivery figures. Analysts raised the price target to $430, but investor concerns persist.

Salīdzinājums

Cenas izmaiņa

Neurocrine Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

10.91% augšup

Prognoze 12 mēnešiem

Vidējais 193.27 USD  10.91%

Augstākais 246 USD

Zemākais 144 USD

Pamatojoties uz 24 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Neurocrine Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

24 ratings

21

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

9 / 342 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
help-icon Live chat